Healio Psoriatic Disease Current Issue
The following articles appeared in the print edition of Healio Psoriatic Disease.
Table of Contents
- Multiple aspects of psoriatic disease addressed with combined clinic model Rebecca L. Forand
-
- Combined clinics for management of psoriatic disease take many forms Joel M. Gelfand, MD, MSCE
- Market gears up for biosimilar boom in 2023 as Humira exclusivity draws to a close Jason Laday
- Cardiovascular risk in PsA greater for new users of IL-12/23, IL-17 vs. TNF inhibitors Jason Laday
- Guselkumab 100 mg improves fatigue in psoriatic arthritis through 1 year Jason Laday
- Methotrexate boosts psoriatic arthritis remission rates for both adalimumab, infliximab Jason Laday
- Methotrexate use associated with COVID-19 hospitalization in patients with psoriasis Rebecca L. Forand
- Patients with psoriasis may have higher mortality rate than general population Rebecca L. Forand
- Study evaluates infection risk in new users of biologics for psoriasis Rebecca L. Forand
-
- Ustekinumab, TNF inhibitors exhibit similar remission, disease activity responses in PsA Jason Laday
- PPACMAN aims to optimize shared psoriatic disease clinics Rebecca L. Forand